JP2018529672A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018529672A5 JP2018529672A5 JP2018511627A JP2018511627A JP2018529672A5 JP 2018529672 A5 JP2018529672 A5 JP 2018529672A5 JP 2018511627 A JP2018511627 A JP 2018511627A JP 2018511627 A JP2018511627 A JP 2018511627A JP 2018529672 A5 JP2018529672 A5 JP 2018529672A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- antibody
- variable region
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 102000000763 Survivin Human genes 0.000 claims 4
- 108010002687 Survivin Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 210000004408 hybridoma Anatomy 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562214242P | 2015-09-04 | 2015-09-04 | |
| US62/214,242 | 2015-09-04 | ||
| PCT/US2016/050391 WO2017041092A2 (en) | 2015-09-04 | 2016-09-06 | Anti-survivin antibodies for cancer therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018529672A JP2018529672A (ja) | 2018-10-11 |
| JP2018529672A5 true JP2018529672A5 (enExample) | 2019-10-17 |
| JP6831836B2 JP6831836B2 (ja) | 2021-02-17 |
Family
ID=58188638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018511627A Active JP6831836B2 (ja) | 2015-09-04 | 2016-09-06 | 癌治療のための抗−サバイビン抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10167340B2 (enExample) |
| EP (1) | EP3344287B1 (enExample) |
| JP (1) | JP6831836B2 (enExample) |
| KR (1) | KR102773176B1 (enExample) |
| CN (1) | CN108883163B (enExample) |
| AU (1) | AU2016318158B2 (enExample) |
| CA (1) | CA2997103A1 (enExample) |
| DK (1) | DK3344287T3 (enExample) |
| ES (1) | ES2883128T3 (enExample) |
| WO (1) | WO2017041092A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3203732A1 (en) * | 2020-12-31 | 2022-07-07 | Health Research, Inc. | Anti-survivin antibodies for treatment of autoimmune diseases |
| CN120028549B (zh) * | 2023-11-23 | 2025-11-28 | 爱威科技股份有限公司 | 检测丙型肝炎病毒核心蛋白结合蛋白6的试剂盒及应用 |
| CN120025432A (zh) * | 2023-11-23 | 2025-05-23 | 爱威科技股份有限公司 | Hcbp6单克隆抗体及其应用 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| CA2271783C (en) | 1996-11-20 | 2013-04-16 | Yale University | Survivin, a protein that inhibits cellular apoptosis, and its modulation |
| WO2001046455A2 (en) * | 1999-12-21 | 2001-06-28 | Yale University | Survivin promotion of angiogenesis |
| US20040110930A1 (en) * | 2002-10-03 | 2004-06-10 | Reinl Stephen J. | Multimeric protein engineering |
| US7342093B2 (en) * | 2004-07-23 | 2008-03-11 | University Of Massachusetts | Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins |
| EP3332808B1 (en) | 2005-03-03 | 2020-09-09 | Immunomedics Inc. | Humanized l243 antibodies |
| EP2287196A3 (en) * | 2006-01-13 | 2011-05-04 | Irm Llc | Antibodies against thymic stromal lymphopoietin receptor for treating allergic diseases |
| PE20090722A1 (es) * | 2007-02-02 | 2009-07-13 | Amgen Inc | Hepcidina, antagonistas de la hepcidina y metodos de uso |
| US8580269B2 (en) | 2007-07-19 | 2013-11-12 | Health Research, Inc. | Survivin peptides for autoimmune therapies |
| EP2178548B1 (en) | 2007-07-19 | 2014-12-24 | Health Research, INC. | Survivin peptides as cancer vaccines |
| JP5812418B2 (ja) * | 2009-04-17 | 2015-11-11 | イムナス・ファーマ株式会社 | Ａβオリゴマーに特異的に結合する抗体およびその利用 |
| CA2898457A1 (en) * | 2013-02-14 | 2014-08-21 | Immunocellular Therapeutics, Ltd. | Ovarian cancer vaccines and vaccination methods |
| CN104098696A (zh) * | 2013-04-07 | 2014-10-15 | 中美华世通生物医药科技（武汉）有限公司 | 一种抗血管内皮生长因子的单克隆抗体 |
-
2016
- 2016-09-06 US US15/257,324 patent/US10167340B2/en active Active
- 2016-09-06 KR KR1020187009445A patent/KR102773176B1/ko active Active
- 2016-09-06 JP JP2018511627A patent/JP6831836B2/ja active Active
- 2016-09-06 ES ES16843185T patent/ES2883128T3/es active Active
- 2016-09-06 CA CA2997103A patent/CA2997103A1/en active Pending
- 2016-09-06 DK DK16843185.6T patent/DK3344287T3/da active
- 2016-09-06 AU AU2016318158A patent/AU2016318158B2/en active Active
- 2016-09-06 EP EP16843185.6A patent/EP3344287B1/en active Active
- 2016-09-06 CN CN201680060066.7A patent/CN108883163B/zh active Active
- 2016-09-06 WO PCT/US2016/050391 patent/WO2017041092A2/en not_active Ceased
-
2018
- 2018-12-27 US US16/233,375 patent/US10738129B2/en active Active
-
2020
- 2020-08-11 US US16/990,622 patent/US11773181B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| JP2022031635A5 (enExample) | ||
| JP2013198490A5 (enExample) | ||
| FI3487882T3 (fi) | Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja | |
| RU2020124153A (ru) | Гуманизированные антитела к cd19 человека и способы их применения | |
| RU2017119543A (ru) | Анти-tim3 антитела и способы их применения | |
| JP2019536470A5 (enExample) | ||
| JP2020500538A5 (enExample) | ||
| JP2014526898A5 (enExample) | ||
| RU2016137110A (ru) | Антитела к компоненту комплемента с5 | |
| JP2017535257A5 (enExample) | ||
| JP2010526028A5 (enExample) | ||
| HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
| HRP20240719T1 (hr) | Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba | |
| ME02678B (me) | Antitijela na ox-40 i postupci njihove primjene | |
| HRP20211444T1 (hr) | Anti-dll3 antitijelo | |
| JP2017052784A5 (enExample) | ||
| RU2016129517A (ru) | Биспецифические антитела к her2 и способы применения | |
| JP2013538057A5 (enExample) | ||
| HRP20221088T1 (hr) | Protutijela i postupci uporabe | |
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| JP2015533795A5 (enExample) | ||
| JP2014158469A5 (enExample) | ||
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| RU2019140602A (ru) | АНТИ-GARP-TGF-β-АНТИТЕЛА |